Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Next Previous
Search
Trial Profile

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Asian PREVAIL
  • Sponsors Astellas Pharma

Most Recent Events

  • 05 Sep 2024 Status changed from active, no longer recruiting to completed.
  • 31 Jul 2024 Planned End Date changed from 30 Jun 2024 to 31 Jul 2024.
  • 26 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top